Use of Procalcitonin (PCT) in Patients Presenting with Overlapping Symptoms
While the Webinar is complete, if you would like to view a free recording of the event, click here.
B·R·A·H·M·S PCT is an invaluable marker to help assess presence or absence of a bacterial infection and can be used as an aid in antibiotic therapy for patients with suspected or confirmed LRTI. This webinar reviews the utility of PCT in the emergency department or inpatient hospital settings, and describes perspectives of three different clinicians and their approach to implementing this biomarker in clinical practice.
• Use PCT to distinguish CHF from pneumonia in patients with dyspnea
• Apply PCT to clinical decision making guiding antibiotic use for patients with acute exacerbations of COPD
• Compare high yield applications of PCT in different hospital settings (ED and inpatient wards)
SEAN-XAVIER NEATH, MD, PHD
Dr. Neath is a fellow of the American College of Emergency Physicians and a member of American Heart Association and Assistant Clinical Professor, Emergency Medicine Department at the University of California San Diego. His research interests include the application of novel biomarkers in the diagnosis and management of acute medical conditions such as sepsis, heart disease, allergy and immunology.
GREGORY B. SEYMANN, MD, SFHM
Dr. Seymann is a hospitalist and Clinical Professor and Vice Chief for Academic Affairs in the Division of Hospital Medicine at the University of California San Diego. His academic interests include systems-based quality improvement and performance measurement for hospitals and physicians, and has investigated the use of procalcitonin for antibiotic stewardship.
MICHAEL R BROYLES, BSPHARM, RPH, PHARMD
Dr. Broyles is Director of Clinical Pharmacy and Laboratory Services at Five Rivers Medical Center in Pocahontas Arkansas and has provided clinical and supervisory functions for over eighteen years. He has implemented an antibiotic monitoring and physician education program resulting in a 400% reduction in antibiotic expenditures per patient and a concurrent 250% reduction in length of stay.